Kristie L. Kahl

On behalf of the National Ovarian Cancer Coalition, CURE spoke with Dr. Debra Richardson, from Stevenson Cancer Center, about the basics of ovarian cancer and its treatments, clinical trials and psychosocial effects.

CURE spoke with Dr. Marty T. Sellers and Dr. Laura M. Kulik, on behalf of the Blue Faery, about liver cancer and disease – its treatments, causes and areas outside of therapy.

CURE spoke with Dr. Eric Jonasch about the National Comprehensive Cancer Network’s Category 1 recommendation for the combination use of Lenvima plus Keytruda for the treatment of front-line renal cell carcinoma. In particular, how it can impact a patient’s treatment journey.

CURE spoke with a cancer rights attorney about what financial toxicity is and ways to address this burden before assistance is needed.

Dr. John Marshall and his wife, Liza, look back on the trials and tribulations of Liza’s triple-negative breast cancer diagnosis – from the perspective of a patient and her husband, the caregiver and oncologist.

“This approval is an important advancement for patients whose disease has relapsed and reinforces the potential for Sarclisa to become a standard of care in relapsed or refractory multiple myeloma,” said Dr. Thomas G. Martin.

CURE® spoke with a cancer rights attorney about employment rights and how patients and their caregivers can learn more to ensure they are being protected.

The agency granted approval to the revised label of Vyxeos to now include treatment for newly diagnosed therapy-related acute myeloid leukemia or disease with myelodysplasia-related changes in pediatric patients aged 1 and older.

CURE® spoke with Monica Fawzy Bryant, chief operating officer of Triage Cancer, about health insurance options and what patients with cancer need to know.

Even as chemotherapy, surgery and radiation remain treatment mainstays, immunotherapy is ready to take the stage.

The agency granted accelerated approval to Pepaxto in combination with dexamethasone in adult patients with relapsed or refractory multiple myeloma, who received at least four prior lines of therapy.

Results from the phase 2 KarMMa trial showed that 73% of patients had a response to the CAR-T cell therapy, including 33% who experienced a complete response or better.

After a recent poll reported negative experiences among Black and Latinx patients during their cancer care, the National Comprehensive Cancer Network, American Cancer Society Cancer Action Network and National Minority Quality Forum recommended practice changes to prevent racial disparities moving forward.

As part of its Speaking Out video series, CURE® spoke with Dr. Steven M. Horwitz on behalf of the Cutaneous Lymphoma Foundation about cutaneous T-cell lymphoma and options for treatment.

Ahead of the release of their book, “Off Our Chests”, Dr. John Marshall and his wife, Liza, look back on the trials and tribulations of Liza’s triple-negative breast cancer diagnosis – from the perspective of a patient and her husband, the caregiver and oncologist.

A meta-analysis found that minimal residual disease positivity after a particular treatment for mantle cell lymphoma can predict worse survival benefit.

The NCCN has updated its recommendations for chronic lymphocytic leukemia and small lymphocytic lymphoma to now include Brukinsa as a first- and second-line therapy in a subgroup of patients.

On behalf of the National Pancreas Foundation, Dr. Andrew M. Lowy offers background on treatments and outcomes for pancreatic cancer.

An interim analysis of the PALLAS study showed that adding Ibrance to endocrine therapy, compared to endocrine therapy alone, after initial treatment ended for patients with HR-positive, HER2-negative, early-stage breast cancer did not extend the length of time before a patient’s disease recurred.

Keytruda monotherapy continued to significantly improve overall and progression-free survival in patients with previously treated, PD-L1–positive advanced non-small cell lung cancer.